| scholarly article | Q13442814 |
| P2093 | author name string | Y Kimura | |
| E von Scheven | |||
| D McCurdy | |||
| C Wallace | |||
| A Eberhard | |||
| A M Reed | |||
| Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators | |||
| C Sandborg | |||
| D D Sherry | |||
| E Silverman | |||
| E Yow | |||
| G C Higgins | |||
| G W Evans | |||
| H I Brunner | |||
| H X Barnhart | |||
| J B Soep | |||
| J Provenzale | |||
| K L Mieszkalski | |||
| L E Schanberg | |||
| L F Imundo | |||
| L Jung | |||
| L Wagner-Weiner | |||
| M Klein-Gitelman | |||
| M Punaro | |||
| N G Singer | |||
| N T Ilowite | |||
| R Silver | |||
| S D Thompson | |||
| S L Bowyer | |||
| S P Ardoin | |||
| P2860 | cites work | The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials | Q24646234 |
| Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors | Q24803555 | ||
| Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus | Q28192401 | ||
| Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial | Q28273112 | ||
| Adherence to Medication | Q28314923 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII) | Q33635924 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
| Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus | Q34338929 | ||
| Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis | Q34604937 | ||
| The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis | Q34845107 | ||
| A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia | Q35122001 | ||
| The management of pediatric systemic lupus erythematosus | Q36577380 | ||
| Statins for treatment of dyslipidemia in chronic kidney disease. | Q36594430 | ||
| Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group | Q36900139 | ||
| Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus | Q37113440 | ||
| Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort | Q37406201 | ||
| Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial | Q38398357 | ||
| Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study | Q40881459 | ||
| Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. | Q40882910 | ||
| The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus | Q40974327 | ||
| The PedsQL: measurement model for the pediatric quality of life inventory | Q41607814 | ||
| Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia | Q42964371 | ||
| Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus | Q43277482 | ||
| Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus | Q44929993 | ||
| Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study | Q44960473 | ||
| Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study | Q46067922 | ||
| Predictors of carotid atherosclerosis in systemic lupus erythematosus. | Q46315593 | ||
| The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial | Q46557882 | ||
| Endothelial function analysis and atherosclerotic risk factors in adolescents with systemic lupus erythematosus | Q46695430 | ||
| Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus | Q46724748 | ||
| Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial | Q46786465 | ||
| Sex differences of carotid intima-media thickness in healthy children and adolescents | Q46792010 | ||
| The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study | Q46895697 | ||
| Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus | Q46973423 | ||
| Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view | Q47437281 | ||
| Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort: effect of age, sex, anthropometry and blood pressure. | Q50852418 | ||
| Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric-onset systemic lupus erythematosus. | Q51754399 | ||
| Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. | Q51918320 | ||
| Morbidity in systemic lupus erythematosus | Q69148719 | ||
| An in vitro study of the effects of lovastatin on human fetal brain cells | Q72136157 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood | Q73167281 | ||
| Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus | Q73904664 | ||
| Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus | Q74198328 | ||
| Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 | ||
| A pravastatin dose-escalation study in systemic lupus erythematosus | Q80089099 | ||
| Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus | Q80607395 | ||
| Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents | Q81044030 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| teenager | Q1492760 | ||
| P304 | page(s) | 285-296 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Use of atorvastatin in systemic lupus erythematosus in children and adolescents | |
| P478 | volume | 64 |
| Q33931813 | A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q39010807 | Advances in the care of children with lupus nephritis |
| Q37547130 | Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis. |
| Q88468246 | American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus |
| Q52867190 | Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. |
| Q27016554 | Cardiovascular disease in lupus: insights and updates |
| Q35121150 | Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions |
| Q36903089 | Cardiovascular risk in pediatric-onset rheumatological diseases |
| Q90415557 | Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management |
| Q38686357 | Childhood Lupus--Diagnosis and Management |
| Q51196776 | Children and adolescents with SLE: not just little adults. |
| Q38909471 | Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study |
| Q39123611 | Dyslipidemia in systemic lupus erythematosus |
| Q92859453 | Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE) |
| Q60922008 | Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus |
| Q92783907 | Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy |
| Q44474173 | Large artery inflammation in systemic lupus erythematosus |
| Q52592135 | Lipid Testing and Statin Prescription among Medicaid Recipients with Systemic Lupus Erythematosus, Diabetes Mellitus and the General Medicaid Population. |
| Q95592748 | Lupus nephritis |
| Q38640910 | Management considerations for childhood-onset systemic lupus erythematosus patients and implications on therapy |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q34343906 | Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus |
| Q42211485 | Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis |
| Q38192577 | New insights into the pathogenesis and management of lupus in children |
| Q28084156 | Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council |
| Q50052184 | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. |
| Q64248332 | Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL) |
| Q84561164 | Paediatric rheumatic disease: lessons from SLE: children are not little adults |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q43900414 | Premature coronary heart disease in SLE: can we prevent progression? |
| Q40459284 | Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. |
| Q38864670 | Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection |
| Q40504034 | Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia |
| Q33922922 | Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. |
| Q38844621 | Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment |
| Q38866356 | Systemic lupus erythematosus: still a challenge for physicians |
| Q36712941 | Taming lupus-a new understanding of pathogenesis is leading to clinical advances |
| Q92935057 | The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus |
| Q47610317 | The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis |
| Q39283399 | The evolving concept of SLE comorbidities. |
| Q38149851 | Transient ischemic attack and stroke in systemic lupus erythematosus |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q37690103 | Update on differences between childhood-onset and adult-onset systemic lupus erythematosus |
| Q34478798 | Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy |
| Q34478814 | Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy |
| Q38591752 | Why are kids with lupus at an increased risk of cardiovascular disease? |
Search more.